BRPI0811745A2 - Uso de compostos de 4-(pirrolidin-1-il)quinolina para matar micro-organismos clinicamente latentes - Google Patents
Uso de compostos de 4-(pirrolidin-1-il)quinolina para matar micro-organismos clinicamente latentesInfo
- Publication number
- BRPI0811745A2 BRPI0811745A2 BRPI0811745-4A2A BRPI0811745A BRPI0811745A2 BR PI0811745 A2 BRPI0811745 A2 BR PI0811745A2 BR PI0811745 A BRPI0811745 A BR PI0811745A BR PI0811745 A2 BRPI0811745 A2 BR PI0811745A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrolidin
- quinoline compounds
- clinically latent
- latent microorganisms
- kill clinically
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0709489.9 | 2007-05-17 | ||
GB0709489A GB0709489D0 (en) | 2007-05-17 | 2007-05-17 | New use |
GB0807591.3 | 2008-04-25 | ||
GB0807591A GB0807591D0 (en) | 2008-04-25 | 2008-04-25 | New use |
PCT/GB2008/001694 WO2008142384A1 (en) | 2007-05-17 | 2008-05-16 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0811745A2 true BRPI0811745A2 (pt) | 2014-11-11 |
BRPI0811745B1 BRPI0811745B1 (pt) | 2019-06-04 |
Family
ID=39672613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811745-4A BRPI0811745B1 (pt) | 2007-05-17 | 2008-05-16 | Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica -- |
Country Status (20)
Country | Link |
---|---|
US (1) | US8759348B2 (pt) |
EP (1) | EP2182950B8 (pt) |
JP (1) | JP5474768B2 (pt) |
KR (1) | KR101599384B1 (pt) |
CN (1) | CN101795688B (pt) |
AU (1) | AU2008252636B2 (pt) |
BR (1) | BRPI0811745B1 (pt) |
CA (1) | CA2684692C (pt) |
DK (1) | DK2182950T3 (pt) |
ES (1) | ES2637999T3 (pt) |
HR (1) | HRP20171553T1 (pt) |
HU (1) | HUE034298T2 (pt) |
IL (1) | IL201392A (pt) |
MX (1) | MX2009012390A (pt) |
NZ (1) | NZ580625A (pt) |
PL (1) | PL2182950T3 (pt) |
PT (1) | PT2182950T (pt) |
RU (1) | RU2520766C2 (pt) |
SI (1) | SI2182950T1 (pt) |
WO (1) | WO2008142384A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010095522A (ja) * | 2008-09-19 | 2010-04-30 | Sumitomo Chemical Co Ltd | 植物病原菌による植物病害を防除又は予防するための農業用組成物 |
PT2552440T (pt) * | 2010-03-30 | 2019-01-10 | Helperby Therapeutics Ltd | Nova combinação e uso |
EP2569302A1 (en) * | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
SI2600869T1 (sl) | 2010-08-05 | 2021-03-31 | Helperby Therapeutics Limited | Kombinacija spojine pirolokinolin in beta-laktamskega protimikrobnega sredstva, mupirocina in klorheksidina |
GB201013207D0 (en) | 2010-08-05 | 2010-09-22 | Helperby Therapeutics Ltd | Novel combination |
GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
WO2016166515A1 (en) | 2015-04-11 | 2016-10-20 | Helperby Therapeutics Limited | Oral composition |
US10329257B2 (en) | 2015-08-13 | 2019-06-25 | The Broad Institute, Inc. | Compositions and methods for treating tuberculosis |
GB201518969D0 (en) | 2015-10-27 | 2015-12-09 | Helperby Therapeutics Ltd | Triple combination |
WO2017120225A1 (en) * | 2016-01-04 | 2017-07-13 | The Johns Hopkins University | Use of low dose emetine for inhibition of human cytomegalovirus (hcmv) |
KR102665309B1 (ko) * | 2016-10-27 | 2024-05-10 | 주식회사 엘지생활건강 | 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물 |
GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
RU2664177C1 (ru) * | 2017-08-07 | 2018-08-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абсцедирующих фурункулов верхней и нижней зон лица |
JP7269917B2 (ja) | 2017-08-17 | 2023-05-09 | イケナ オンコロジー, インコーポレイテッド | Ahr阻害剤およびその使用 |
US10668046B2 (en) * | 2017-12-18 | 2020-06-02 | Ansella Therapeutics, Inc. | Compositions and methods for preventing and treating conditions |
CN110897032A (zh) * | 2019-11-19 | 2020-03-24 | 华南理工大学 | 一种发酵饲料蛋白及其制备方法与应用 |
RU2758056C2 (ru) * | 2019-11-21 | 2021-10-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Препарат для лечения отитов бактериальной и грибковой этиологии у собак |
CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
KR102461715B1 (ko) * | 2020-10-12 | 2022-11-02 | 대한민국 | 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도 |
CN114831924A (zh) * | 2021-03-17 | 2022-08-02 | 武汉恒信源药业有限公司 | 一种乌洛托品及其化合物的阴道局部给药制剂及用途 |
CN113528388A (zh) * | 2021-07-19 | 2021-10-22 | 海南大学 | 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用 |
AU2022380979A1 (en) | 2021-11-02 | 2024-06-06 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
EP1395564B1 (en) | 2001-05-21 | 2008-02-27 | F. Hoffmann-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide y receptor |
US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
CA2468159A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
BR0307441A (pt) * | 2002-02-04 | 2005-01-04 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade |
CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
CA2495723C (en) * | 2002-08-19 | 2011-05-24 | Avi Elbaz | Proprioceptive/kinesthetic apparatus and method |
CN101817815A (zh) * | 2002-10-10 | 2010-09-01 | 莫弗凯姆联合化学股份公司 | 具有杀菌活性的化合物 |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
GB0522715D0 (en) * | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
-
2008
- 2008-05-16 US US12/600,470 patent/US8759348B2/en not_active Expired - Fee Related
- 2008-05-16 CA CA2684692A patent/CA2684692C/en not_active Expired - Fee Related
- 2008-05-16 CN CN200880016456.XA patent/CN101795688B/zh not_active Expired - Fee Related
- 2008-05-16 NZ NZ580625A patent/NZ580625A/en not_active IP Right Cessation
- 2008-05-16 PL PL08750626T patent/PL2182950T3/pl unknown
- 2008-05-16 AU AU2008252636A patent/AU2008252636B2/en not_active Ceased
- 2008-05-16 KR KR1020097026394A patent/KR101599384B1/ko active IP Right Grant
- 2008-05-16 RU RU2009146828/15A patent/RU2520766C2/ru not_active IP Right Cessation
- 2008-05-16 HU HUE08750626A patent/HUE034298T2/en unknown
- 2008-05-16 ES ES08750626.7T patent/ES2637999T3/es active Active
- 2008-05-16 WO PCT/GB2008/001694 patent/WO2008142384A1/en active Application Filing
- 2008-05-16 PT PT87506267T patent/PT2182950T/pt unknown
- 2008-05-16 BR BRPI0811745-4A patent/BRPI0811745B1/pt not_active IP Right Cessation
- 2008-05-16 EP EP08750626.7A patent/EP2182950B8/en not_active Not-in-force
- 2008-05-16 JP JP2010507981A patent/JP5474768B2/ja not_active Expired - Fee Related
- 2008-05-16 MX MX2009012390A patent/MX2009012390A/es active IP Right Grant
- 2008-05-16 SI SI200831883T patent/SI2182950T1/en unknown
- 2008-05-16 DK DK08750626.7T patent/DK2182950T3/da active
-
2009
- 2009-10-11 IL IL201392A patent/IL201392A/en active IP Right Grant
-
2017
- 2017-10-13 HR HRP20171553TT patent/HRP20171553T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0811745B1 (pt) | 2019-06-04 |
NZ580625A (en) | 2011-12-22 |
SI2182950T1 (en) | 2018-01-31 |
CA2684692A1 (en) | 2008-11-27 |
WO2008142384A1 (en) | 2008-11-27 |
CA2684692C (en) | 2016-07-05 |
KR101599384B1 (ko) | 2016-03-03 |
MX2009012390A (es) | 2010-06-23 |
RU2520766C2 (ru) | 2014-06-27 |
CN101795688B (zh) | 2015-05-20 |
HRP20171553T1 (hr) | 2017-12-15 |
DK2182950T3 (da) | 2017-11-06 |
JP2010527346A (ja) | 2010-08-12 |
AU2008252636B2 (en) | 2013-10-31 |
PL2182950T3 (pl) | 2018-01-31 |
IL201392A0 (en) | 2010-05-31 |
JP5474768B2 (ja) | 2014-04-16 |
HUE034298T2 (en) | 2018-02-28 |
EP2182950B1 (en) | 2017-07-19 |
AU2008252636A1 (en) | 2008-11-27 |
US8759348B2 (en) | 2014-06-24 |
CN101795688A (zh) | 2010-08-04 |
RU2009146828A (ru) | 2011-06-27 |
KR20100021476A (ko) | 2010-02-24 |
IL201392A (en) | 2016-03-31 |
ES2637999T3 (es) | 2017-10-18 |
PT2182950T (pt) | 2017-09-11 |
US20100305065A1 (en) | 2010-12-02 |
EP2182950B8 (en) | 2017-08-23 |
EP2182950A1 (en) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0811745A2 (pt) | Uso de compostos de 4-(pirrolidin-1-il)quinolina para matar micro-organismos clinicamente latentes | |
CY2019010I1 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
BRPI0918586A2 (pt) | compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico | |
LTPA2017039I1 (lt) | Pirolopirimidino junginiai, kaip CDK inhibitoriai | |
SMT201500213B (it) | Alcune triazolopirazine, loro composizioni e metodi d'uso | |
BRPI0911688A2 (pt) | "compostos de pirimidina, composições e métodos de uso" | |
SMT201500206B (it) | Composti spiro-ossindolici e loro uso come agenti terapeutici | |
ZA200804454B (en) | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | |
SMT201400055B (it) | Composti di tioacetato, composizioni e metodi d'uso | |
EA201100037A1 (ru) | Органические соединения | |
BR112012003661A2 (pt) | "compostos de biarila e métodos de uso dos mesmos." | |
BRPI0810863A2 (pt) | Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease. | |
BRPI0807487A2 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
DK2315756T3 (da) | 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase | |
BRPI1009208A2 (pt) | "suspensão oleosa contendo bactérias probióticas para uso pediátrico" | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
BRPI0818003A2 (pt) | inibidores de csf-1r, composições e métodos de uso | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
BRPI0812159A2 (pt) | inibidores de csf-1r, composições e métodos de uso | |
BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
BR112013008704A2 (pt) | "dispensador com bobina coletora de resíduos, e métodos de uso" | |
BR112012031861A2 (pt) | uso de 5a-androstano (alquil)-3b, 5, 6b-triol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |